Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated whole poliovirus particles. After injection, the antigens are processed by antigen‑presenting cells, prompting B‑cells to produce neutralising antibodies. These antibodies block future infection by live poliovirus, providing long‑lasting humoral immunity without the risk of viral replication.

The specific dose and schedule of Imovax Polio are determined by the prescribing healthcare professional based on age, immunisation history and local guidelines. The prescriber selects the appropriate volume and timing for the primary series and any required booster doses.

Safety data for Imovax Polio in pregnancy are limited, so it should be administered only if the potential benefit justifies any potential risk. Limited information is available for breastfeeding; the decision should consider the importance of protecting the infant against poliovirus infection.

To order Imovax Polio, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imovax Polio is an inactivated poliovirus vaccine (IPV) whereas oral polio vaccine (OPV) contains live attenuated virus. IPV does not carry a risk of vaccine‑derived poliovirus and is preferred in settings where OPV‑related outbreaks are a concern. Both provide immunity, but IPV requires injection and multiple doses for optimal protection.

Imovax Polio must be stored refrigerated at 2‑8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage preserves vaccine potency.

The vaccine is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the anterolateral thigh for infants or the deltoid muscle for older children and adults. The injection site should be cleaned with an antiseptic before administration.

Serious but rare risks include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and prolonged high fever. Any signs of a severe reaction, such as difficulty breathing, swelling of the face or throat, or persistent high fever, require immediate medical evaluation.

Individuals with a known severe allergy to any component of the vaccine, including the inactivated virus or stabilisers, should not receive Imovax Polio. Persons with acute moderate or severe illness should defer vaccination until recovery. The vaccine is contraindicated in those with a history of severe vaccine‑related adverse events.